# PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011 - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/pet-drug-applications-content-and-format-for-ndas-and-andas-attachment-i-sample-formats-for-chemistry-manufacturing-and-controls-cmc-sections_2011/a4320966-98dd-464c-8b5e-d455c45c3f0e

> FDA guidance document: PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011. Issue date: September 01, 2011. Get complete insights and analysis.

---

## Details

- Title: PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2011-09-01
- Last Changed: 2020-05-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2000-D-1542">FDA-2000-D-1542</a>

## Related Documents

- [CPG Sec  490100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval](https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-490100-process-validation-requirements-for-drug-products-and-active-pharmaceutical-ingredients-subject-to-pre-market-approval/864a062a-ddcb-4710-b694-d588ace094c0)
- [E12A Principles for Clinical Evaluation of New Antihypertensive Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/e12a-principles-for-clinical-evaluation-of-new-antihypertensive-drugs/a715b1f0-1946-46b1-8a7f-cd01a428224d)
- [CPG Sec 490100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval](https://www.globalkeysolutions.net/guidances/guidance-document/cpg-sec-490100-process-validation-requirements-for-drug-products-and-active-pharmaceutical-ingredients-subject-to-pre-market-approval/b94c2509-66e7-4f39-b0f9-fad032bc48c3)